D
Diasorin
Multinational biotech company
About Diasorin
DiaSorin—publicly listed on the FTSE MIB Index since 2007— is an Italy-based company globally operating in laboratory diagnostics. It develops, produces and markets testing devices and equipment that enable doctors worldwide to make accurate diagnosis. Every second, 10 people in the world encounter DiaSorin. DiaSorin’s success lies in its ongoing biotechnological innovation driven by large-scale investments in research and development. Every year, the Company launches about 10 new diagnostic tests. Research is at the core of the Group’s achievements in the world of laboratory diagnostics. More than 200 employees are committed to developing state-of-the-art specialized testing solutions that assist doctors and laboratory teams in the difficult task of providing effective and efficient results, specifically meeting with their niche testing needs. The choice to develop niche test services alongside more common diagnostic tests has allowed the Group to become a leading player in a very innovative and competitive market and to be internationally recognized as the “Specialist” in the diagnostic field. DiaSorin is present worldwide with 26 companies, 4 branches, 5 production sites and 5 research and development centers. The company operates directly in Europe, Israel, the United States, Canada, Mexico, Brazil, China, India and Australia. The rest of the world is served by more than 200 independent distributors with whom the Group maintains strong relationships in order to offer the best possible service to all its customers.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2007
- Employees
- 2,877
- Open positions
- 78
- Dealroom signal
- 51.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Infections and Infectious Diseases, Research and Development, Screening, observatoire healthtech
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Apr 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Nov 2020 | $820K | — | Undisclosed | — |
| GRANT✓Other financing | Jul 2020 | $111K | — | HHS Administration for Strategic Preparedness and Response | — |
Growth signals
Latest recorded traffic for Diasorin is 27K monthly website visits, up 35% over the last three months. Diasorin's team grew 86.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Diasorin in the Saluggia ecosystem
The Diasorin office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
HHS Administration for Strategic Preparedness and Response
Other known investors1 additional known investor
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Diasorin on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Diasorin’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









